Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 216 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: beta blockers Clear all
Enrolling by invitation Not applicable Interventional

N-of-1 Trial to Promote Beta-Blocker Titration in Heart Failure

NCT07489352
View directory record Official record
Conditions
Heart Failure, Beta-blocker, Older Adults
Interventions
N-of-1 trials, Enhanced usual care
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 7:16 AM EDT
Completed Not applicable Interventional Results available

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

NCT01117454
View directory record Official record
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
Flecainide Acetate, Placebo, Beta blocker
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
5 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 25, 2026, 7:16 AM EDT
Terminated Phase 4 Interventional Results available

Risk Factor Control Before Orthopedic Surgery

NCT01837069
View directory record Official record
Conditions
Osteoarthritis, Cardiovascular Disease
Interventions
Metoprolol, Lisinopril, Atorvastatin, Lifestyle counseling
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 25, 2026, 7:16 AM EDT
Completed Phase 3 Interventional

A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension

NCT00200434
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2005 · Synced Oct 25, 2026, 7:16 AM EDT
Withdrawn Not applicable Interventional

Heart Rate Variability (HRV) to Evaluate Surgical Risk on Patients on Beta Blockers

NCT01330654
View directory record Official record
Conditions
Cardiac Event Risk
Interventions
metoprolol
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Oct 25, 2026, 7:16 AM EDT
Not listed Not applicable Interventional

Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator

NCT04504188
View directory record Official record
Conditions
Cardiomyopathies, Heart Failure
Interventions
Heart Rate Monitor Enhanced Treatment Optimization
Device
Lead sponsor
Zoll Medical Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Cincinnati, Ohio • Kingwood, Texas • McKinney, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 25, 2026, 7:16 AM EDT
Completed No phase listed Observational

Preserving Kidney Function in Children With Chronic Kidney Disease

NCT05169411
View directory record Official record
Conditions
Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Pediatric Kidney Disease
Interventions
Blood pressure, Urine protein
Diagnostic Test
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 17 Years
Enrollment
20,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 25, 2026, 7:16 AM EDT
Terminated Phase 4 Interventional Results available

Alternative in Beta Blocker Intolerance: The ABBI Trial

NCT00893984
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Nebivolol
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 25, 2026, 7:16 AM EDT
Completed No phase listed Observational

Quantification of Myocardial Blood Flow Using Dynamic PET/CTA Fused Imagery

NCT04221594
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Invasive Cardiac Catheterization (ICA), Coronary Computed Tomographic Angiogram (CCTA), Dynamic Cardiac Positron Emission Tomography (dPET)
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia • Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 25, 2026, 7:16 AM EDT
Withdrawn Phase 3 Interventional

Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE

NCT00787436
View directory record Official record
Conditions
Gastrointestinal Hemorrhage, Portal Hypertension
Interventions
Thalidomide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 25, 2026, 7:16 AM EDT
Completed Phase 3 Interventional

A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients

NCT00200460
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2005 · Synced Oct 25, 2026, 7:16 AM EDT
Withdrawn Phase 4 Interventional

Assessment of Intravenous Rate Control Response in Atrial Fibrillation Trial (AIRCRAFT)

NCT04234477
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Beta-blocker strategy, Calcium channel blocker strategy, Physician preference strategy
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 25, 2026, 7:16 AM EDT
Completed Phase 2 Interventional Results available

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

NCT01847001
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm, Breast Cancer
Interventions
Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim
Drug · Other · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 25, 2026, 7:16 AM EDT
Completed Not applicable Interventional

BAROSTIM NEO Hypertension Pivotal Trial

NCT01679132
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
BAROSTIM NEO System and Medical Management
Device
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 7:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Race, Natriuretic Peptides and Physiological Perturbations

NCT03070184
View directory record Official record
Conditions
Healthy, Pre Hypertension
Interventions
Exercise capacity VO2 max determination, Standardized meals, Exercise challenge, Metoprolol Succinate ER
Other · Dietary Supplement · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 25, 2026, 7:16 AM EDT
Terminated Early Phase 1 Interventional Results available

Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study

NCT05096884
View directory record Official record
Conditions
Tachycardia, Dyspnea, COVID-19
Interventions
Metoprolol Succinate
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 25, 2026, 7:16 AM EDT
Completed Phase 4 Interventional Results available

Reducing Total Cardiovascular Risk in an Urban Community

NCT00241904
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Coronary Disease, Diabetes Mellitus, Atherosclerosis, Cerebral Arteriosclerosis, Hypertension
Interventions
Lifestyle Changes, Antiplatelet Agents, Beta Blocker, ACE Inhibitors
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 80 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 25, 2026, 7:16 AM EDT
Completed Phase 3 Interventional

Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension

NCT00145236
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2005 · Synced Oct 25, 2026, 7:16 AM EDT
Terminated Phase 4 Interventional

BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT)

NCT00433043
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Beta blocker (carvedilol or metoprolol succinate), CRT (cardiac resynchronization therapy)
Drug · Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
New York, New York • Rochester, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Oct 25, 2026, 7:16 AM EDT
Completed No phase listed Observational Results available

Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study

NCT01099397
View directory record Official record
Conditions
Prediabetic State
Interventions
Oral glucose tolerance test
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 25, 2026, 7:16 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine

NCT03836664
View directory record Official record
Conditions
Migraine
Interventions
Timolol, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 25, 2026, 7:16 AM EDT
Completed Not applicable Interventional

The Home Blood Pressure (BP) Trial

NCT05159999
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis
Interventions
Dry weight target adjustment, Anti-hypertensive medications
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 25, 2026, 7:16 AM EDT
Not listed Phase 4 Interventional

Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

NCT02660866
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Placebo + background APT + SMT, Vorapaxar 2.08 mg/d + background APT + SMT.
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
40 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
12
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 25, 2026, 7:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Brown Adipose Tissue Activation on Insulin Sensitivity in Humans

NCT01791114
View directory record Official record
Conditions
Insulin Sensitivity, Obesity
Interventions
Cold exposure, Cold exposure plus propranolol, Thermoneutral Conditions, Cold water consumption, Tepid water consumption, Exercise, Meal consumption
Other
Lead sponsor
Rutgers University
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 25, 2026, 7:16 AM EDT